Glycogen synthase kinase 3β inhibitors prevent hepatitis C virus release/assembly through perturbation of lipid metabolism

Direct acting antivirals against hepatitis C virus (HCV) have markedly improved cure rates in the past few years. However, they are expensive, with only few targeting host cell factors, and affecting virus assembly and release. Huh7.5 cells infected with a JFH-1 clone of HCV were treated with two di...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarhan, Mohammed A., Abdel-Hakeem, Mohamed S., Mason, Andrew L., Tyrrell, D. Lorne, Houghton, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451429/
https://www.ncbi.nlm.nih.gov/pubmed/28566716
http://dx.doi.org/10.1038/s41598-017-02648-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451429/
https://www.ncbi.nlm.nih.gov/pubmed/28566716
http://dx.doi.org/10.1038/s41598-017-02648-6

Ejemplares similares